目的 探討燈盞生脈膠囊聯(lián)合奧拉西坦注射液治療輕中度血管性癡呆的療效。方法 選取濮陽(yáng)市人民醫(yī)院2012年1月—2015年3月收治的輕中度血管性癡呆患者90例,采用隨機(jī)數(shù)字表法分為治療組(45例)和對(duì)照組(45例)。所有患者均給予常規(guī)降血脂、抗血小板聚集治療,對(duì)照組給予靜脈滴注奧拉西坦注射液4 g,加入到0.9%生理鹽水500 mL,1次/d。治療組在對(duì)照組基礎(chǔ)上口服燈盞生脈膠囊,2粒/次,1次/d。兩組均連續(xù)治療12周。治療前后采用簡(jiǎn)易智能精神狀態(tài)量表(MMSE)和蒙特利爾認(rèn)知評(píng)估量表(MoCA)評(píng)價(jià)患者認(rèn)知功能;采用日常生活能力量表(ADL)評(píng)價(jià)患者日常生活自理能力;比較兩組患者血管內(nèi)中膜厚度(IMT)。結(jié)果 治療后2、4、12周,兩組MMSE、MoCA評(píng)分均顯著上升(P< 0.05),且治療組MMSE、MoCA評(píng)分顯著高于對(duì)照組(P< 0.05);治療后2、4、12周,兩組ADL評(píng)分均顯著升高(P< 0.05),且治療組ADL評(píng)分顯著高于對(duì)照組(P< 0.05)。治療后兩組IMT均顯著降低(P< 0.05),且治療組IMT顯著低于對(duì)照組(P< 0.05)。結(jié)論 燈盞生脈膠囊聯(lián)合奧拉西坦注射液治療輕中度血管性癡呆療效確切,可顯著改善患者的認(rèn)知功能和日常生活行為,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Dengzhan Shengmai Capsules combined with Oxiracetam Injection in treatment of mild or moderate vascular dementia. Methods Patients (90 cases) with mild or moderate vascular dementia in People's Hospital of Puyang from January 2012 to March 2015 were randomly divided into control and treatment groups, and each group had 45 cases. All patients were treated with lipid reduction and antiplatelet aggregation. The patients in the control group were iv administered with Oxiracetam Injection 4 g added into 0.9% normal saline 500 mL, once daily. The patients in the treatment group were po administered with Shengmai Capsules on the basis of the control group, 2 capsules/ time, once daily. Two groups were treated for 12 weeks. Before and after treatment, the cognitive functions were evaluated with Mini Mental State (MMSE) scale and Montreal Cognitive Assessment (MoCA) scale, daily life ability was evaluated with Activity of Daily Living (ADL) scale, and intima-media thickness (IMT) were compared between two groups. Results After treatment for 2, 4, and 12 weeks, the MMSE score and MoCA score of both groups were obviously increased (P < 0.05), and the indexes of the treatment group were higher than those in the control group (P < 0.05). After treatment for 2, 4, and 12 weeks, the ADL score of both groups were significantly increased (P < 0.05), and the indexes of the treatment group were higher than those in the control group (P < 0.05). After treatment, the IMT of both groups were significantly decreased (P < 0.05), and the indexes of the treatment group were obviously lower than those in the control group (P < 0.05). Conclusion Dengzhan Shengmai Capsules combined with Oxiracetam Injection has curative effect in treatment of mild or moderate vascular dementia, could improve the cognitive function and daily life ability, and prevent occurrence and development of atherosclerotic plaque, which has a certain clinical application value.